Teratoma classification: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
Line 4: Line 4:


==Classification==
==Classification==
:* 1. '''World Health Organization classification of CNS teratoma'''<ref name="pmid9046301">{{cite journal| author=Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N et al.| title=Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. | journal=J Neurosurg | year= 1997 | volume= 86 | issue= 3 | pages= 446-55 | pmid=9046301 | doi=10.3171/jns.1997.86.3.0446 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9046301  }} </ref>
There is no established system for the classification of [disease name].
:::* Teratoma.
::::* Immature.
::::* Mature.
::::* Teratoma with malignant transformation.


:* 2. '''Childhood Extracranial teratoma classification'''
OR
::* 2.1 GCTs arise from primordial germ cells, which migrate during embryogenesis from the yolk sac through the mesentery to the gonads.<ref name="pmid6343221">{{cite journal| author=Dehner LP| title=Gonadal and extragonadal germ cell neoplasia of childhood. | journal=Hum Pathol | year= 1983 | volume= 14 | issue= 6 | pages= 493-511 | pmid=6343221 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6343221  }} </ref><ref name="pmid18381640">{{cite journal| author=McIntyre A, Gilbert D, Goddard N, Looijenga L, Shipley J| title=Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. | journal=Genes Chromosomes Cancer | year= 2008 | volume= 47 | issue= 7 | pages= 547-57 | pmid=18381640 | doi=10.1002/gcc.20562 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18381640  }} </ref> Childhood extracranial GCTs can be divided into the following two types:
::::* Gonadal.
::::* Extragonadal.
::* 2.2 Most childhood extragonadal teratoma arise in midline sites (i.e., sacrococcygeal, mediastinal, and retroperitoneal); the midline location may represent aberrant embryonic migration of the primordial germ cells.Childhood extracranial teratoma are broadly classified as the following:
::::* Mature teratomas.
::::* Immature teratomas.
::* 2.3 Pediatric teratoma Biology
:::* The following biologically distinct subtypes of teratoma are found in children and adolescents:
::::* Testicular.
::::* Ovarian.
::::* Extragonadal extracranial.
:*3. '''Cellular Classification of Ovarian Teratoma'''
::* The following histologic subtypes have been described.<ref name="pmid8381708">{{cite journal| author=Gershenson DM| title=Update on malignant ovarian germ cell tumors. | journal=Cancer | year= 1993 | volume= 71 | issue= 4 Suppl | pages= 1581-90 | pmid=8381708 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8381708  }} </ref><ref>Serov SF, Scully RE, Robin IH: International Histologic Classification of Tumours: No. 9. Histological Typing of Ovarian Tumours. Geneva: World Health Organization, 1973.</ref>
:::* Teratoma.
::::* Immature.
::::* Mature.
::::::* Solid.
::::::* Cystic.
:::::::* [[Dermoid cyst]] (mature cystic teratoma).
:::::::* [[Dermoid cyst]] with malignant transformation.
:::* Monodermal and highly specialized.
:::::* Struma ovarii.
:::::* Carcinoid.
:::::* Struma ovarii and carcinoid.
:::::* Others (e.g., malignant neuroectodermal and ependymoma).
:* 4. '''Cellular Classification of Testicular Cancer''' <ref>Woodward PJ, Heidenreich A, Looijenga LHJ, et al.: Germ cell tumours. In: Eble JN, Sauter G, Epstein JI, et al.: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, 2004, pp 221-49.</ref><ref>Ulbright TM, Berney DM: Testicular and paratesticular tumors. In: Mills SE, Carter D, Greenson JK, et al., eds.: Sternberg's Diagnostic Surgical Pathology. Philadelphia, Pa: Lippincott Williams & Wilkins, 2010, pp 1944-2004.</ref><ref>Bosi GJ, Feldman DR, Bajorin DE, et al.: Cancer of the testis. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2011, pp 1280-1301</ref>
::* 4.1 Malignant pure germ cell tumor (showing a single-cell type):


::::* Teratoma.
[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
::* 4.2 Malignant mixed germ cell tumor (showing more than one histologic pattern):
 
::::* Embryonal carcinoma and teratoma with or without seminoma.
* [Group1]
::::* Yolk sac tumor and teratoma with or without seminoma.
* [Group2]
* [Group3]
* [Group4]
 
OR
 
[Disease name] may be classified into [large number > 6] subtypes based on:
 
* [Classification method 1]
* [Classification method 2]
* [Classification method 3]
 
[Disease name] may be classified into several subtypes based on:
 
* [Classification method 1]
* [Classification method 2]
* [Classification method 3]
 
OR
 
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
 
OR
 
'''If the staging system involves specific and characteristic findings and features:'''
 
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
 
OR
 
The staging of [malignancy name] is based on the [staging system].
 
OR
 
There is no established system for the staging of [malignancy name].
 
:::::::*  


==References==
==References==

Revision as of 18:23, 21 August 2019

Teratoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Teratoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Teratoma classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Teratoma classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Teratoma classification

CDC on Teratoma classification

Teratoma classification in the news

Blogs on Teratoma classification

Directions to Hospitals Treating Teratoma

Risk calculators and risk factors for Teratoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]

Classification

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups:

  • [Group1]
  • [Group2]
  • [Group3]
  • [Group4]

OR

[Disease name] may be classified into [large number > 6] subtypes based on:

  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

[Disease name] may be classified into several subtypes based on:

  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features:

According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

References